New Report on Estradiol Ranges in Postmenopausal Women Released

Updated recommendations to establish normal estradiol reference ranges have been released in a new report from the North American Menopause Society (NAMS).

The report is based on a symposium called “Workshop on Normal Reference Ranges for Estradiol in Postmenopausal Women,” that was held in September 2019, in Chicago, Ill., and featured 28 presentations. The Endocrine Society and the Partnership for the Accurate Testing of Hormones (PATH) were supporters of this symposium.

PATH was established in 2010 to help the clinical, medical, and public health communities improve patient care through more accurate and reliable hormone tests. Improved patient care through the universal use of accurate and reliable hormone tests in healthcare and research is PATH’s chief goal, which is why it was one of the participants in this workshop.

The overarching goal of the symposium was to review existing analytical methodologies for measuring estradiol in postmenopausal women and to assess existing data and study cohorts of postmenopausal women for their suitability to establish normal postmenopause reference ranges.

The anticipated outcome of the workshop was to develop recommendations for establishing normal reference ranges generated with a standardized and certified assay that could be adopted by clinical and research communities.

Aside from the Endocrine Society and PATH, the other organizations that lent support for the symposium include: NAMS, the American Society for Reproductive Medicine, the Centers for Disease Control and Prevention, the International Society for the Study of Women’s Sexual Health, the University of Virginia, Division of Endocrinology and Metabolism, and the International Menopause Society.

Funding companies for the workshop included: Abbott Laboratories, Ansh Labs, ARUP Labs, Endoceutics, Novo Nordisk, Quest Diagnostics, and TherapeuticsMD.

The report from the workshop is published in the June 2020 issue of Menopause. More information about accurate hormone assays and PATH is available at


You may also like

  • Individuals Taking Class of Steroid Medications at High Risk for COVID-19

    JCEM Editors examine pandemic’s impact on endocrine patients in editorial Individuals taking a class of steroid hormones called glucocorticoids for conditions such as asthma, allergies and arthritis on a routine basis may be unable to mount a normal stress response and are at high risk if they are infected with the virus causing COVID-19, according…

  • Endocrine Society Elects Wysham as 2021-2022 President

    Five endocrinologists to join Board of Directors Endocrine Society members have elected Carol H. Wysham, MD, to serve as the organization’s President for the 2021-2022 term. Wysham is an endocrinologist at Rockwood/MultiCare Health Systems in Spokane, Wash., and Clinical Professor of Medicine at the University of Washington. She will serve as President-Elect for a year…

Find more in